How the PFF’s 5-year plan seeks to expand access to expert care

The European Medicines Agency (EMA) has awarded orphan drug designation to Rein Therapeutics’ lead drug candidate, LTI-03, which is being developed to help preserve lung function in people with idiopathic pulmonary fibrosis (IPF). The designation follows a positive opinion from the EMA’s Committee for Orphan Medicinal Products, which evaluates…

Artificial intelligence (AI) touches many aspects of both our professional and personal lives. One of the earliest recognitions of AI dates back more than 75 years to when Alan Turing, an English mathematician and computer scientist, pondered the question, “Can machines think?” Today, the answer seems closer to…

Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data announced by its developer, Gri Bio. Data from the Phase 2a study (NCT06331624) broadly suggest that GRI-0621 is…

Over the holidays, for the first time in a long while, my home was full of voices, laughter, movement, and the comfort of family. I hosted the gathering, something I hadn’t been able to do in years. For someone like me living with pulmonary fibrosis, hosting a holiday party…

Individuals with lingering signs of pulmonary fibrosis (PF) months after recovering from COVID-19 were found to be older and to have significantly lower levels than normal of beneficial gut bacteria, particularly Bifidobacterium and Blautia, a new study reports. In follow-up experiments, a mouse model of PF given supplements of…

When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in the early days of 2017, it seemed like my world moved in slow motion. Just a few months earlier, as my diagnostic journey began in the fall of 2016, my doctors sensed something was wrong, but no one could…